Showing 1441-1450 of 1635 results for "".
- Study Reveals Significant Restoration of Retinal and Visual Function Following Gene Therapyhttps://modernod.com/news/study-reveals-significant-restoration-of-retinal-and-visual-function-following-gene-therapy/2478443/A breakthrough study, led by researchers from the University of California, Irvine, showed significant restoration of retinal and visual function following gene therapy in mice models suffering from inherited retinal disease. Published in Nature Biomedical Engineering, the paper,
- Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 for Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-treats-first-patients-in-three-phase-3-studies-of-ksi-301-for-retinal-diseases/2478361/Kodiak Sciences announced that the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER, and BEACON studies, three pivotal phase 3 studies of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in treatment-naïve patients with diabetic macular edema (GLEAM
- Trump Signs Executive Orders on Preexisting Condition Protections, Surprise Billinghttps://modernod.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/President Donald Trump signed an executive order that declares it a national policy to protect patients with preexisting conditions regardless of the fate of the Affordable Care Act (ACA)—but just how they’ll force insurers to comply remains unclear, according to a FierceHealthcare
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- Aviceda Therapeutics Appoints Biopharma and Business Veterans to its Board of Directorshttps://modernod.com/news/aviceda-therapeutics-appoints-biopharma-and-business-veterans-to-its-board-of-directors/2478284/Aviceda Therapeutics has announce the appointment of Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA, to their board of directors, effective immediately. Aviceda is a preclinical stage biotech company focused on the next generation of glyco-immune therapeutics utilizing the Glyco-Code technolog
- Medical Optometry America to Open First Practice Location in Southcentral Pennsylvaniahttps://modernod.com/news/medical-optometry-america-to-open-first-practice-location-in-southcentral-pennsylvania/2478237/Medical Optometry America (MOA) announced their first practice location will open in Shrewsbury, Pennsylvania in late 2020 and will be led by MOA’s Regional Clinical Director Leslie O’Dell, OD, FAAO. As the first national optometric brand focused exclusively on medical eye care, MOA is lau
- NIH Panel Finds “Insufficient” Data to Support Use of Plasma for COVID-19https://modernod.com/news/nih-panel-finds-insufficient-data-to-support-use-of-plasma-for-covid-19/2478235/A panel of the National Institutes of Health (NIH) concluded that “there are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19.” The review by the COVID-19 Treatment Guidelines Panel comes shortly after the FDA issued an
- Academy 2020 Moves Online Due to COVID-19https://modernod.com/news/academy-2020-moves-online-due-to-covid-19/2478154/As a direct result of the COVID-19 pandemic, the American Academy of Optometry’s (AAO) announced that Academy 2020 Nashville will be held entirely as a virtual meeting renamed Academy 2020 At Home. “We listened to our stakeholders and watched the national health situation very car
- Dosing Begins in Moderna’s Late-Stage Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/dosing-begins-in-modernas-late-stage-study-of-covid-19-vaccine-candidate/2478085/Moderna announced that patient dosing started in the phase 3 COVE study of its mRNA-based vaccine candidate against the novel coronavirus, sending company shares up as much as 11.3% on Monday. The trial of mRNA-1273 is being conducted in collaboration with the US National Institute of Allergy and
- COVID-19 Vaccine Candidate Heads To Widespread Testing In U.S.https://modernod.com/news/covid-19-vaccine-candidate-heads-to-widespread-testing-in-u-s/2478083/The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday, according to an NPR